Does current evidence justify prostate cancer screening in Europe?

This publication has 12 references indexed in Scilit:

• Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower
  JAMA, 2005
• Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
  New England Journal of Medicine, 2005
• THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?
  Journal of Urology, 2004
• Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
  New England Journal of Medicine, 2004
• Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer
  JNCI Journal of the National Cancer Institute, 2003
• Screening for prostate cancer
  The Lancet, 2003
• Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut
  BMJ, 2002
• VALIDITY OF THE PROSTATE SPECIFIC ANTIGEN TEST FOR PROSTATE CANCER SCREENING: FOLLOWUP STUDY WITH A BANK OF 21,000 SERA IN FINLAND
  Journal of Urology, 2001
• Comparison of trends in prostate-cancer mortality in England and Wales and the USA
  The Lancet, 2000
• Urinary and Sexual Function After Radical Prostatectomy for Clinically Localized Prostate Cancer
  JAMA, 2000